- Florida-Grown Cucumbers Behind Salmonella Outbreak, CDC Warns
- Nebraska First State to Ban Soda, Energy Drinks From SNAP Program
- FDA Limits COVID-19 Boosters to Seniors, Other High-Risk Groups
- Deaths Waiting For Lung Donation Have Dropped Under New Guidelines
- Battling Multiple Chronic Illnesses Can Double Risk Of Depression
- 9 In 10 U.S. Teens Have Been Cyberbullied
- Blood, Urine Tests Can Identify Level Of Ultra-Processed Food In Diet
- Many Seniors Fear Cataract Surgery
- Bodybuilding Linked To Sudden Cardiac Deaths
- Possible Plastic Contamination Prompts Nationwide Ice Cream Recall
FDA Approves Antibiotic for Skin Infections

The U.S. Food and Drug Administration has approved the intravenous antibiotic Dalvance (dalbavancin) to treat methicillin-resistant Staphylococcus aureus (MRSA) and other potentially deadly bacterial skin infections resistant to older antibiotics.
Dalvance was given priority review and designated a “Qualified Infectious Disease Product” since it’s meant to treat serious bacterial or fungal infections, the FDA said in a news release.
The drug’s safety and effectiveness were evaluated in clinical studies involving nearly 1,300 people with acute bacterial skin infections. The most common side effects were nausea, headache and diarrhea. Study participants who took Dalvance also showed a higher-than-expected incidence of elevated liver enzymes in one screening test, the agency said.
Dalvance is marketed by Durata Therapeutics of Chicago.
More information
The FDA has more about this approval.
Source: HealthDay
Copyright © 2025 HealthDay. All rights reserved.